Clinical Trials Logo

Filter by:
NCT ID: NCT06106373 Recruiting - Clinical trials for Hearing Loss, Sensorineural

iotaSOFT Pediatric Study

Start date: May 17, 2022
Phase: N/A
Study type: Interventional

Prospective, non-randomized, open-label study to evaluate the safety and efficacy of the iotaSOFT Insertion System when used to assist electrode array insertion during cochlear implant surgery in a pediatric population.

NCT ID: NCT06106360 Recruiting - Solid Tumor Clinical Trials

A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy

Start date: October 26, 2023
Phase:
Study type: Observational [Patient Registry]

A pilot study using remote monitoring technology developed by Locus Health in cancer patients undergoing chemotherapy treatment.

NCT ID: NCT06106334 Completed - Obesity Clinical Trials

Effect of Administration of Itraconazole on the Pharmacokinetics of S-309309 in Healthy Participants

Start date: November 15, 2023
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to determine the effect of repeated administration of itraconazole on the pharmacokinetic (PK) profile of S-309309; and the PK of S-309309 following administration of S-309309 alone and co-administration with itraconazole

NCT ID: NCT06106308 Recruiting - Clinical trials for Metastatic Colorectal Cancer

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Start date: February 27, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess 2 different doses of onvansertib to select the lowest dose that is maximally effective, and to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of onvansertib in combination with FOLFIRI + bevacizumab or FOLFOX + bevacizumab in patients with KRAS or NRAS-mutated metastatic colorectal cancer (CRC) in the first-line setting.

NCT ID: NCT06106295 Recruiting - Clinical trials for Mild Autonomous Cortisol Secretion (MACS)

Metyrapone for Mild Autonomous Cortisol Secretion (MACS)

Start date: December 19, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out whether the study drug, metyrapone, is safe and effective in treating participants with Mild Autonomous Cortisol Secretion (MACS).

NCT ID: NCT06106282 Recruiting - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Breast Cancer Survivors Who Experience Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)

Start date: July 12, 2023
Phase:
Study type: Observational

This study evaluates the effectiveness of a cognitive behavioral multicomponent treatment program in improving pain, mood, and functioning while reducing medication non-adherence in breast cancer patients with Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS).

NCT ID: NCT06106269 Recruiting - Internal Hemorrhoid Clinical Trials

Outcomes and Quality of Life Following Rectal Artery Embolization for Bleeding Internal Hemorrhoids

HEMBO-1
Start date: June 7, 2024
Phase:
Study type: Observational

This study will assess how effective and safe rectal artery embolization works to treat symptomatic bleeding predominant internal hemorrhoids.

NCT ID: NCT06106256 Recruiting - Motion Sickness Clinical Trials

Three-Axis Wearable Adaptive Vestibular Stimulator

Start date: November 15, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to improve current galvanic vestibular stimulation (GVS) technology to ease the motion sickness often associated with virtual reality (VR) simulation.

NCT ID: NCT06106204 Enrolling by invitation - Pneumonia Clinical Trials

Reducing Overuse of Antibiotics at Discharge Home

ROAD Home
Start date: November 1, 2023
Phase: N/A
Study type: Interventional

The goal of this two-arm parallel cluster-randomized trial of 40 hospitals is to test the effectiveness of the ROAD Home Intervention on days of antibiotic overuse at discharge in patients hospitalized with community-acquired pneumonia (CAP) or urinary tract infection (UTI). The main question it aims to answer is: Does an antibiotic stewardship approach that is customized to the needs, goals, and resources of a hospital (i.e., the ROAD Home Intervention) compared to standard stewardship approaches reduce antibiotic overuse at discharge in hospitalized patients with CAP and UTI? The investigators will randomize 20 hospitals in the Michigan Hospital Medicine Safety Consortium (HMS) to the intervention group and 20 HMS hospitals to the "usual care" control group. During the study the investigators will: (a) assess baseline performance, existing stewardship strategies, hospital priorities, and resources; (b) develop a customized discharge stewardship "suite" for each intervention hospital based on the findings of the baseline assessment and informed by the ROAD Home Framework; and (c) support hospitals in selecting strategies and creating an implementation blueprint to be implemented over 12 to 15 months. After the intervention period, the investigators will compare days of antibiotic overuse at discharge and patient outcomes between intervention and "usual care" hospitals. It is hypothesized that hospitals randomized to the ROAD Home Intervention will have fewer days of antibiotic overuse at discharge compared to "stewardship as usual" control hospitals.

NCT ID: NCT06106191 Not yet recruiting - Clinical trials for Chronic Low-back Pain

Integrative Mindfulness-Based Predictive Approach for Chronic Low Back Pain Treatment

IMPACT
Start date: June 2024
Phase: N/A
Study type: Interventional

This study will identify unique signatures that people have which can cause pain by evaluating biological, psychological, and social markers using artificial intelligence. These markers can be used to accurately predict the response of diverse individuals with chronic low back pain (cLBP) to Mindfulness-Based Stress Reduction. This will help enhance clinician decision-making and the targeted treatment of chronic pain. The overall objective is to use a unique machine learning (ML) approach to determine the biomarker signature of persons undergoing mindfulness based stress reduction (MBSR) treatment for their chronic low back pain (cLBP). This signature will facilitate clinical prediction and monitoring of patient response to MBSR treatment. The design of the study is a single-arm clinical trial of the evidence-based MBSR program for patients with cLBP.